Lipidomics-driven drug discovery and delivery strategies in glioblastoma DOI Creative Commons
Xiaohui Weng, Michael Gonzalez, Jeannes Angelia

et al.

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2024, Volume and Issue: 1871(3), P. 167637 - 167637

Published: Dec. 23, 2024

With few viable treatment options, glioblastoma (GBM) is still one of the most aggressive and deadly types brain cancer. Recent developments in lipidomics have demonstrated potential lipid metabolism as a therapeutic target GBM. The thorough examination lipids biological systems, or lipidomics, essential to comprehending changed profiles found GBM, which are linked tumor's ability grow, survive, resist treatment. use drug delivery discovery examined this study, focusing on how it may be used find new biomarkers, create multi-target directed ligands, improve systems. We also cover FDA-approved medications, clinical trials that lipid-targeted medicines, integration with other omics technologies. This study emphasizes possible tool developing more effective methods for GBM by exploring various lipid-centric techniques.

Language: Английский

Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges DOI Open Access
Attila A. Seyhan

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7974 - 7974

Published: July 21, 2024

Gliomas, particularly glioblastoma (GBM), represent the most prevalent and aggressive tumors of central nervous system (CNS). Despite recent treatment advancements, patient survival rates remain low. The diagnosis GBM traditionally relies on neuroimaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scans postoperative confirmation via histopathological molecular analysis. Imaging techniques struggle to differentiate between tumor progression treatment-related changes, leading potential misinterpretation delays. Similarly, tissue biopsies, while informative, are invasive not suitable for monitoring ongoing treatments. These challenges have led emergence liquid biopsy, through blood samples, a promising alternative monitoring. Presently, cerebrospinal fluid (CSF) sampling offers minimally means obtaining tumor-related information guide therapy. idea that any biofluid tests can be used screen many cancer types has huge potential. Tumors release various components into bloodstream other biofluids, including cell-free nucleic acids microRNAs (miRNAs), circulating DNA (ctDNA), cells (CTCs), proteins, extracellular vesicles (EVs) exosomes, metabolites, factors. factors been shown cross blood-brain barrier (BBB), presenting an opportunity well real-time assessment distinct genetic, epigenetic, transcriptomic, proteomic, metabolomic changes associated with brain tumors. their potential, clinical utility biopsy-based biomarkers is somewhat constrained by limitations absence standardized methodologies CSF collection, analyte extraction, analysis methods, small cohort sizes. Additionally, biopsies offer more precise insights morphology microenvironment. Therefore, objective biopsy should complement enhance diagnostic accuracy patients providing additional alongside traditional biopsies. Moreover, utilizing combination diverse biomarker may effectiveness compared solely relying one category, potentially improving sensitivity specificity addressing some existing GBM. This review presents overview latest research found in discusses diagnostic, predictive, prognostic indicators, future perspectives.

Language: Английский

Citations

12
Lipid metabolism: the potential therapeutic targets in glioblastoma DOI Creative Commons
Lu Lu, Yan Zhang,

Yuzhong Yang

et al.

Cell Death Discovery, Journal Year: 2025, Volume and Issue: 11(1)

Published: March 17, 2025

Abstract Glioblastoma is a highly malignant tumor of the central nervous system with high mortality rate. The mechanisms driving glioblastoma onset and progression are complex, posing substantial challenges for developing precise therapeutic interventions to improve patient survival. Over century ago, discovery Warburg effect underscored importance abnormal glycolysis in tumors, marking pivotal moment cancer research. Subsequent studies have identified mitochondrial energy conversion as fundamental driver growth. Recently, lipid metabolism has emerged critical factor cell survival, providing an alternative source. Research shown that reprogrammed glioblastoma, playing vital role shaping biological behavior cells. In this review, we aim elucidate impact on tumorigenesis explore potential targets. Additionally, provide insights into regulatory govern metabolism, emphasizing roles key genes regulators involved essential metabolic process.

Language: Английский

Citations

0
Metabolic Plasticity of Glioblastoma Cells in Response to DHODH Inhibitor BAY2402234 Treatment DOI Creative Commons
Ayenachew Bezawork‐Geleta, Diane Moujalled, David P. De Souza

et al.

Metabolites, Journal Year: 2024, Volume and Issue: 14(8), P. 413 - 413

Published: July 27, 2024

Glioblastoma (IDH-wildtype) represents a formidable challenge in oncology, lacking effective chemotherapeutic or biological interventions. The metabolic reprogramming of cancer cells is hallmark tumor progression and drug resistance, yet the role glioblastoma during treatment remains poorly understood. dihydroorotate dehydrogenase (DHODH) inhibitor BAY2402234 blood–brain barrier penetrant showing efficiency vivo models many brain cancers. In this study, we investigated effect regulating phenotype EGFRWT EGFRvIII patient-derived cell lines. Our findings reveal selective cytotoxicity toward subtypes with minimal on patient cells. At sublethal doses, induces triglyceride synthesis at expense membrane lipid fatty acid oxidation cells, while these effects are not observed Furthermore, reduced abundance signaling species glioblastoma. This study elucidates genetic mutation-specific plasticity efficacy response to treatment, offering insights into therapeutic avenues for precision medicine approaches.

Language: Английский

Citations

1
Size matters: Biomolecular compositions of small and large extracellular vesicles in the urine of glioblastoma patients DOI Creative Commons
Susannah Hallal,

Liam A. Sida,

Ágota Tűzesi

et al.

Journal of Extracellular Biology, Journal Year: 2024, Volume and Issue: 3(11)

Published: Nov. 1, 2024

Abstract The promise of urinary extracellular vesicles (uEVs) in biomarker discovery is emerging. However, the characteristics and compositions different uEV subpopulations across normal physiological pathological states require rigorous explication. We recently reported proteomic signatures small (s)‐uEVs (<200 nm membranous nanoparticles) described putative biomarkers corresponding to diagnosis, tumour burden recurrence lethal adult primary brain tumour, glioblastoma. Here, we comprehensively characterise populations with significantly mean mode particle sizes obtained by differential centrifugation at 100,000 × g (100K‐uEVs; smaller) 17,000 (17K‐uEVs; larger) using Fourier‐transform infrared spectroscopy quantitative data‐independent acquisition mass spectrometry. show distinct differences protein lipid content, prominent secondary structures, proteome distributions between that can distinguish glioblastoma patients from healthy controls correspond clinically relevant changes (i.e., treatment resistance). Among key findings a seven‐protein panel associated 17K‐uEVs could all accurately classify 98.2% samples. These novel, significant demonstrate both offer individual combined potential. Further research warranted elucidate complete diagnostic, prognostic, predictive capabilities often‐neglected 17K‐uEV populations.

Language: Английский

Citations

1
Material informatics-driven insights into brain cancer nanocarriers: A bibliometric comparison of PLGA vs. liposomes DOI Creative Commons

Brilly Andro Makalew,

Syauqi Abdurrahman Abrori

OpenNano, Journal Year: 2024, Volume and Issue: 21, P. 100225 - 100225

Published: Dec. 11, 2024

Language: Английский

Citations

1
Lipidomics-driven drug discovery and delivery strategies in glioblastoma DOI Creative Commons
Xiaohui Weng, Michael Gonzalez, Jeannes Angelia

et al.

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Journal Year: 2024, Volume and Issue: 1871(3), P. 167637 - 167637

Published: Dec. 23, 2024

With few viable treatment options, glioblastoma (GBM) is still one of the most aggressive and deadly types brain cancer. Recent developments in lipidomics have demonstrated potential lipid metabolism as a therapeutic target GBM. The thorough examination lipids biological systems, or lipidomics, essential to comprehending changed profiles found GBM, which are linked tumor's ability grow, survive, resist treatment. use drug delivery discovery examined this study, focusing on how it may be used find new biomarkers, create multi-target directed ligands, improve systems. We also cover FDA-approved medications, clinical trials that lipid-targeted medicines, integration with other omics technologies. This study emphasizes possible tool developing more effective methods for GBM by exploring various lipid-centric techniques.

Language: Английский

Citations

0